CMS Open Payments · Program Year 2024
OrthoPediatrics Corp.
OrthoPediatrics Corp. reported $2,735,134.04 across General Payments, Research, and Ownership to 849 physicians and teaching hospitals across 849 transactions.
- $2.7M
- All-tracks total
- 849
- Transactions
- 849
- Recipients
- +$764.0K
- General Payments vs PY2023
OrthoPediatrics Corp. reported $2,735,134.04 across all CMS Open Payments tracks (General + Research + Ownership) to 849 physicians and teaching hospitals in Program Year 2024 - ranking #386 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $2,735,134.04, averaging $3.2K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer orthopediatrics-corp OrthoPediatrics Corp.
$2.7M · #386/1,925 · 0.0% industry · PY2024
- TOT $2.7M
- RANK #386
- SHARE 0.0%
- TXN 849
- RCP 849
- CAT 7
- GEN $2.7M
- ΔGEN +$764.0K
- TOP1 11.7%
- PY 2024
Volume peers
Nearest volume peer: Provisio Medical, Inc. ($2.7M)
OrthoPediatrics Corp. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
OrthoPediatrics Corp.'s CMS-reported General Payments increased by $764.0K (+38.8%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: ORTHOPEDIATRICS CORP.PY2023: ORTHOPEDIATRICS CORP.PY2024: OrthoPediatrics Corp.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,971,164.12
- PY2024
- $2,735,134.04
What the Data Shows for OrthoPediatrics Corp.
Rank #386 of 1,925 companies in CMS Open Payments for 2024 belongs to OrthoPediatrics Corp., which reported $2,735,134.04 across 849 transactions to 849 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $3.2K per transaction and $3.2K per recipient.
"Royalty or License" leads the 7-category general-payment breakdown below at $1.4M (51.7% of General Payments, 94 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
"Royalty or License" leads OrthoPediatrics Corp.'s 7-category general-payment breakdown at $1.4M, 51.7% of the reported total.
OrthoPediatrics Corp. reports 7 general-payment categories - the top three are Royalty or License (51.7%), Consulting Fee (18.4%), and Grant (16.4%). The remaining 4 categories make up 13.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How OrthoPediatrics Corp. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $1.4M | 94 | 51.7% |
| Consulting Fee | $502.5K | 175 | 18.4% |
| Grant | $447.2K | 67 | 16.4% |
| Compensation for Services Other Than Consulting | $181.5K | 5 | 6.6% |
| Acquisitions | $125.6K | 4 | 4.6% |
| Travel and Lodging | $57.5K | 381 | 2.1% |
| Food and Beverage | $5.9K | 123 | 0.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,065,705.52 (39.0%) of $2,735,134.04 in this company's General Payments records across 280 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for OrthoPediatrics Corp.
The five named recipients with the highest reported General Payments from this company
- 1
Peter Stevens
$320,625.82 across 12 reported transactions
- 2
University Of North Carolina Hosp.
$230,765.80 across 20 reported transactions
- 3
Dror Paley
$200,245.14 across 4 reported transactions
- 4
George Dyer
$182,932.54 across 8 reported transactions
- 5
Joe Gordon
$131,136.22 across 5 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as OrthoPediatrics Corp.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about OrthoPediatrics Corp..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with OrthoPediatrics Corp..
Showing 6 of 1,924 companies with CMS-reported payment data.
Johnson & Johnson Health Care Systems Inc.
Tulsa Dental Products LLC
Janssen Global Services, LLC
Cook Medical LLC
Canon Medical Systems Corporation
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.